Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF REVENUE RECOGNITION (Details)

v3.25.1
SCHEDULE OF REVENUE RECOGNITION (Details) - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Product Information [Line Items]    
Total net revenue $ 1,853,597 $ 2,406,391
Health Care, Patient Service [Member]    
Product Information [Line Items]    
Total net revenue [1] 1,570,382 2,149,049
Histology Service Fees [Member]    
Product Information [Line Items]    
Total net revenue 263,754 237,972
Medical Director Fees [Member]    
Product Information [Line Items]    
Total net revenue 16,588 16,058
Department of Defense Observational Studies [Member]    
Product Information [Line Items]    
Total net revenue 2,885
Other Revenues [Member]    
Product Information [Line Items]    
Total net revenue $ 2,873 $ 427
[1] Patient services fees include direct billing for CyPath® Lung diagnostic test of approximately $169,000 and $45,000 for the three months ended March 31, 2025 and 2024, respectively.